Cargando…

Two-year antibody persistence in children vaccinated at 12–15 months with a measles-mumps-rubella virus vaccine without human serum albumin

One combined measles-mumps-rubella (MMR) vaccine without Human Serum Albumin (HSA) is currently licensed in the USA (M-M-R II; Merck, USA) and another has been developed (Priorix™ [MMR-RIT, GSK, Belgium]). In this follow-up study, children from USA or Puerto Rico, who had received one dose of M-M-R...

Descripción completa

Detalles Bibliográficos
Autores principales:	Berry, Andrea A., Abu-Elyazeed, Remon, Diaz-Perez, Clemente, Mufson, Maurice A., Harrison, Christopher J., Leonardi, Michael, Twiggs, Jerry D., Peltier, Christopher, Grogg, Stanley, Carbayo, Antonio, Shapiro, Steven, Povey, Michael, Baccarini, Carmen, Innis, Bruce L., Henry, Ouzama
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2017
Materias:	Research Papers
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5512763/ https://www.ncbi.nlm.nih.gov/pubmed/28481690 http://dx.doi.org/10.1080/21645515.2017.1309486

Ejemplares similares

Immunogenicity and safety of a second dose of a measles-mumps-rubella vaccine administered to healthy participants 7 years of age or older: A phase III, randomized study
por: Abu-Elyazeed, Remon, et al.
Publicado: (2018)

Clinical trials show similar safety outcomes including febrile convulsion rates for GSK’s and Merck’s measles-mumps-rubella (MMR) vaccines
por: Habib, Md Ahsan, et al.
Publicado: (2023)

Immunogenicity and safety of combined measles-mumps-rubella-varicella vaccine using new measles and rubella working seeds in healthy children in Taiwan and Singapore: A phase II, randomized, double-blind trial
por: Huang, Li-Min, et al.
Publicado: (2013)

Safety and Immunogenicity of Human Serum Albumin-Free MMR Vaccine in US Children Aged 12–15 Months
por: Mufson, Maurice A., et al.
Publicado: (2015)

Immunogenicity and Safety of a Measles-Mumps-Rubella Vaccine Administered as a First Dose to Children Aged 12 to 15 Months: A Phase III, Randomized, Noninferiority, Lot-to-Lot Consistency Study
por: Klein, Nicola P, et al.
Publicado: (2019)

Immunogenicity and safety of a tetravalent measles-mumps-rubella-varicella vaccine: an open-labeled, randomized trial in healthy Korean children
por: Cha, Sung-Ho, et al.
Publicado: (2014)

571. A Report of the Postmarketing Spontaneous Safety Data over 24 Years for GSK’s Measles-Mumps-Rubella (MMR) Vaccine
por: Singh, Tina, et al.
Publicado: (2022)

Difficulties in Eliminating Measles and Controlling Rubella and Mumps: A Cross-Sectional Study of a First Measles and Rubella Vaccination and a Second Measles, Mumps, and Rubella Vaccination
por: Wang, Zhifang, et al.
Publicado: (2014)

2467. Timeliness of Childhood Vaccination With the Combination Measles–Mumps–Rubella–Varicella Vaccine vs. the Separate Measles–Mumps–Rubella and Varicella Vaccines in the United States
por: Wolfson, Lara, et al.
Publicado: (2018)

Measles-Mumps-Rubella Vaccine and COVID-19 Relationship
por: Özdemir, Öner
Publicado: (2020)

Immunogenicity and safety of early vaccination with two doses of a combined measles-mumps-rubella-varicella vaccine in healthy Indian children from 9 months of age: a phase III, randomised, non-inferiority trial
por: Lalwani, Sanjay, et al.
Publicado: (2015)

An Economic Analysis of Mumps Vaccination in Fiji: Static Model Simulation of Routine Measles–Mumps–Rubella (MMR) Vaccination Instead of Current Measles–Rubella (MR) Vaccination
por: Oh, Chunghyeon, et al.
Publicado: (2022)

Knowledge and Practice of Parents Towards Measles, Mumps and Rubella Vaccination
por: Hussein, Siti Zuhaida, et al.
Publicado: (2022)

Safety of measles, mumps, and rubella vaccine in adolescents and adults in the vaccine safety Datalink
por: Hanson, Kayla E., et al.
Publicado: (2023)

Partial third nerve palsy after Measles Mumps Rubella vaccination
por: Manzotti, Francesca, et al.
Publicado: (2010)

Efficacy of intralesional injection of mumps-measles-rubella vaccine in patients with wart
por: Zamanian, Abbas, et al.
Publicado: (2014)

Perspectives on the Measles, Mumps and Rubella Vaccination among Somali Mothers in Stockholm
por: Jama, Asha, et al.
Publicado: (2018)

Reply to Özdemir, “Measles-Mumps-Rubella Vaccine and COVID-19 Relationship”
por: Fidel, Paul L., et al.
Publicado: (2020)

Measles-mumps-and-rubella-virus-vaccine: Aseptic meningitis: case report
Publicado: (2021)

Measles mumps and rubella virus vaccine: Various toxicities: case report
Publicado: (2022)

Response to Measles, Mumps and Rubella (MMR) Vaccine in Transfusion-Dependent Patients
por: Casale, Maddalena, et al.
Publicado: (2021)

Buschke–Lowenstein tumor treated with intralesional measles, mumps, and rubella vaccine
por: Deshmukh, Ashish, et al.
Publicado: (2022)

1339 Measles and Mumps Antibody Response in Young Adults after a Third Dose of Measles-Mumps-Rubella Vaccine
por: Fiebelkorn, Amy Parker, et al.
Publicado: (2014)

Mumps Antibody Response in Young Adults After a Third Dose of Measles-Mumps-Rubella Vaccine
por: Fiebelkorn, Amy Parker, et al.
Publicado: (2014)

Measles–mumps–rubella vaccination and respiratory syncytial virus-associated hospital contact
por: Sørup, Signe, et al.
Publicado: (2015)

Comparison of Intralesional Measles, Mumps, Rubella Vaccine and Needling in the Treatment of Recurrent Warts
por: Kolte, Surabhi R., et al.
Publicado: (2020)

Safety of measles, mumps, and rubella vaccine in egg allergy: in vivo and in vitro management
por: Magistà, Stefania, et al.
Publicado: (2020)

1209. Seroprevalence of Measles, Mumps, and Rubella in Korean Healthcare Workers and Strategy for Vaccination
por: Ju Choo, Eun, et al.
Publicado: (2019)

Anticancer Activity of Measles–Mumps–Rubella MMR Vaccine Viruses against Glioblastoma
por: Khalid, Zumama, et al.
Publicado: (2023)

Influence of measles-mumps-rubella vaccine series initiation and completion on influenza vaccination among adolescents
por: Beeninga, F. Trent, et al.
Publicado: (2022)

A novel cancer vaccine for melanoma based on an approved vaccine against measles, mumps, and rubella
por: Fusciello, Manlio, et al.
Publicado: (2022)

Benign Recurrent Sixth (Abducens) Nerve Palsy following Measles-Mumps-Rubella Vaccination
por: Bourtoulamaiou, Areti, et al.
Publicado: (2015)

Measles, mumps, and rubella vaccine in genital warts: A case report of two patients
por: Meena, Dilip, et al.
Publicado: (2018)

Measles, mumps and rubella vaccine 12 months after hematopoietic stem cell transplantation
por: Randi, Bruno Azevedo, et al.
Publicado: (2023)

Efficacy of Intralesional Measles Mumps Rubella Vaccine in the Treatment of Verruca Vulgaris: An Interventional Study
por: Surani, Ashma S, et al.
Publicado: (2023)

Barriers to measles mumps rubella vaccine acceptance in the three southern border provinces of Thailand
por: Sirithammaphan, Uraiwan, et al.
Publicado: (2023)

2763. Uptake and Safety of Measles-Mumps-Rubella (MMR) Vaccine in Adolescents and Adults in the Vaccine Safety Datalink
por: Hanson, Kayla E, et al.
Publicado: (2019)

1148. Long-term Persistence of Measles and Rubella Virus Neutralizing Antibody Levels among Adults with Three Doses of Measles-Mumps-Rubella Vaccine
por: Alonge, Oluwakemi, et al.
Publicado: (2023)

Mumps Postexposure Prophylaxis with a Third Dose of Measles-Mumps-Rubella Vaccine, Orange County, New York, USA
por: Fiebelkorn, Amy Parker, et al.
Publicado: (2013)

Measles, Mumps, Rubella serology in juvenile idiopathic arthritis
por: Heijstek, MW, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_nrgql66nsdqimmp28qrfggr2gs